Latest Information
January 30th, 2018
Patients with advanced renal cell carcinoma had an improved time to deterioration (TTD) and similar quality of life (QoL) after treatment with cabozantinib compared with everolimus, according to a study published in the Journal of Clinical Oncology.1
December 15th, 2017
Patients who underwent cytoreductive nephrectomy for metastatic non-clear cell renal cell carcinoma had a significantly decreased risk of cancer-related mortality.
October 13th, 2017
Cancer-specific mortality among patients who undergo surgery for non-metastatic renal cell carcinoma (RCC) vary according to histologic subtypes of the malignancy, new findings suggest.
Print this page Tell A Friend Add to Favorites

Cytoreductive Nephrectomy Benefits for Metastatic RCC Demonstrated

December 15th, 2017

Jody A. Charnow (Renal & Urology News)


Cytoreductive nephrectomy for metastatic non-clear cell renal cell carcinoma (RCC) may decrease cancer-specific mortality (CSM), a recent study suggests.

In a study of 851 patients with metastatic non-clear cell RCC, researchers found that patients who underwent cytoreductive nephrectomy had a significant 62% decreased risk of CSM than those who did not, according to results published online ahead of print in European Urology Focus.

The 2-year cumulative CSM rate was 52.6% for those who underwent cytoreductive nephrectomy group versus 77.7% for those who did not. The investigators observed a survival benefit of cytoreductive nephrectomy across histologic subtypes (papillary, chromophobe, collecting duct carcinoma).

Among contemporary patients (those diagnosed during 2010–2014), cytoreductive nephrectomy was associated with a 68% decreased risk of CSM.

Of the 851 patients, 67.6% underwent cytoreductive nephrectomy. The study population had a median age of 62 years and a median tumor size of 80 mm; 74.4% were men and 71.4% were white. Overall, 555 patients died during the study period.

Reference

Marchioni M, Bandini M, Preisser F, et al. Survival cytoreductive nephrectomy in metastatic non-clear cell renal cell carcinoma patients: A population-based study. Eur Urol Focus 2017; published online ahead of print.

Filed Under: Uncategorized